Ancestim: Difference between revisions
Content deleted Content added
Updating {{infobox_drug}} (changes to verified fields - updated 'ChemSpiderID_Ref') per Chem/infobox_drug validation (report errors or bugs) |
Rescuing 1 sources and tagging 0 as dead. #IABot (v1.2.4) |
||
| Line 40: | Line 40: | ||
| molecular_weight = |
| molecular_weight = |
||
}} |
}} |
||
'''Ancestim''' is a recombinant methionyl human [[stem cell factor]], branded by [[Amgen]] as StemGen. It was developed by Amgen and sold to Biovitrium, now [[Swedish Orphan Biovitrum]], in December, 2008.<ref name=BiovitriumDeal>Amgen press office. [http://www.amgen.com/media/biovitrum_amgen_deal.html Biovitrum Closes Product Acquisition Deal with Amgen]</ref> |
'''Ancestim''' is a recombinant methionyl human [[stem cell factor]], branded by [[Amgen]] as StemGen. It was developed by Amgen and sold to Biovitrium, now [[Swedish Orphan Biovitrum]], in December, 2008.<ref name=BiovitriumDeal>Amgen press office. [http://www.amgen.com/media/biovitrum_amgen_deal.html Biovitrum Closes Product Acquisition Deal with Amgen] {{wayback|url=http://www.amgen.com/media/biovitrum_amgen_deal.html |date=20120703015728 }}</ref> |
||
It is a 166 amino acid protein produced by [[Escherichia coli|E. coli]] bacteria into which a gene has been inserted for soluble human [[stem cell factor]].<ref name="pmid15322567">{{cite journal |vauthors=da Silva MG, Pimentel P, Carvalhais A |title=Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection |journal=Bone Marrow Transplant. |volume=34 |issue=8 |pages=683–91 |year=2004 |pmid=15322567 |doi=10.1038/sj.bmt.1704602|display-authors=etal}}</ref> It has a monomeric molecular weight of approximately 18,500 daltons and normally exists as a noncovalently associated dimer. The protein has an [[amino acid]] sequence that is identical to the natural sequence predicted from human [[DNA]] sequence analysis, except for the addition of an N-terminal methionine retained after expression in [[Escherichia coli|E. coli]]. Because Ancestim is produced in [[Escherichia coli|E. coli]], it is nonglycosylated. Ancestim is supplied as a sterile, white, preservative-free, lyophilised powder for reconstitution and administration as a subcutaneous (SC) injection and is indicated for use in combination with [[filgrastim]] for mobilizing peripheral [[hematopoietic stem cells]] for later [[Hematopoietic stem cell transplantation|transplanation]] in certain cancer patients.<ref>[http://www.sobi.com/en/Healthcare-Professionals/Products-alphabetical-list/Stemgen/ Sobi's StemGen page]]</ref> |
It is a 166 amino acid protein produced by [[Escherichia coli|E. coli]] bacteria into which a gene has been inserted for soluble human [[stem cell factor]].<ref name="pmid15322567">{{cite journal |vauthors=da Silva MG, Pimentel P, Carvalhais A |title=Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection |journal=Bone Marrow Transplant. |volume=34 |issue=8 |pages=683–91 |year=2004 |pmid=15322567 |doi=10.1038/sj.bmt.1704602|display-authors=etal}}</ref> It has a monomeric molecular weight of approximately 18,500 daltons and normally exists as a noncovalently associated dimer. The protein has an [[amino acid]] sequence that is identical to the natural sequence predicted from human [[DNA]] sequence analysis, except for the addition of an N-terminal methionine retained after expression in [[Escherichia coli|E. coli]]. Because Ancestim is produced in [[Escherichia coli|E. coli]], it is nonglycosylated. Ancestim is supplied as a sterile, white, preservative-free, lyophilised powder for reconstitution and administration as a subcutaneous (SC) injection and is indicated for use in combination with [[filgrastim]] for mobilizing peripheral [[hematopoietic stem cells]] for later [[Hematopoietic stem cell transplantation|transplanation]] in certain cancer patients.<ref>[http://www.sobi.com/en/Healthcare-Professionals/Products-alphabetical-list/Stemgen/ Sobi's StemGen page]]</ref> |
||
Revision as of 14:17, 12 October 2016
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | s.c. injection only, premedication with H1 and H2 antihistamines and beta-receptor agonists for bronchodilation |
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 2.5 h |
| Excretion | renal: 90% |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Ancestim is a recombinant methionyl human stem cell factor, branded by Amgen as StemGen. It was developed by Amgen and sold to Biovitrium, now Swedish Orphan Biovitrum, in December, 2008.[1]
It is a 166 amino acid protein produced by E. coli bacteria into which a gene has been inserted for soluble human stem cell factor.[2] It has a monomeric molecular weight of approximately 18,500 daltons and normally exists as a noncovalently associated dimer. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine retained after expression in E. coli. Because Ancestim is produced in E. coli, it is nonglycosylated. Ancestim is supplied as a sterile, white, preservative-free, lyophilised powder for reconstitution and administration as a subcutaneous (SC) injection and is indicated for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells for later transplanation in certain cancer patients.[3]
References
- ^ Amgen press office. Biovitrum Closes Product Acquisition Deal with Amgen Archived 2012-07-03 at the Wayback Machine
- ^ da Silva MG, Pimentel P, Carvalhais A, et al. (2004). "Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection". Bone Marrow Transplant. 34 (8): 683–91. doi:10.1038/sj.bmt.1704602. PMID 15322567.
- ^ Sobi's StemGen page]
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |